Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer

Published:2018-09-04 Issue:2 Volume:123 Page:300-306
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Fenioux Charlotte¹^ORCID,Louvet Christophe¹,Charton Emilie²,Rozet Francois³,Ropert Stanislas⁴,Prapotnich Dominique³,Barret Eric³,Sanchez-Salas Rafael³,Mombet Annick³,Cathala Nathalie³,Joulia Marie-Liesse¹,Molitor Jean-Luc¹,Henriques Julie²,Bonnetain Franck²,Cathelineau Xavier³,Bennamoun Mostefa¹

Affiliation:

1. Department of Medical Oncology; Institut Mutualiste Montsouris; Paris France

2. Methodology and Quality of Life Unit in Oncology; University Hospital of Besançon; Besançon France

3. Department of Urology; Institut Mutualiste Montsouris; Paris France

4. Department of Medical Oncology; Antony's Private Hospital; Antony France

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14511/fullpdf

Reference19 articles.

1. Global cancer incidence and mortality rates and trends-an update;Torre;Cancer Epidemiol Biomark Prev,2016

2. Global cancer statistics 2012 https://www.ncbi.nlm.nih.gov/pubmed/25651787

3. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Parker;Ann Oncol,2015

4. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer;Mitsiades;Cancer Res,2013

5. CYP17 inhibition as a hormonal strategy for prostate cancer;Reid;Nat Clin Pract Urol,2008

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of PSA Response after Dexamethasone Switch during Abiraterone Acetate + Prednisolone Treatment of Metastatic Castration-Resistant Prostate Cancer Patients;Cancers;2024-08-03

2. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-10

3. Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes;eLife;2022-06-28

4. Metronomic Chemotherapy in Prostate Cancer;Journal of Clinical Medicine;2022-05-18

5. Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer;Asian Journal of Andrology;2022